🧾 Pain and Aspergillosis: What Patients Need to Know

Including the Role of Your Healthcare Team

Pain is an often overlooked but important part of living with chronic aspergillosis — whether it’s CPA, ABPA, SAFS, or aspergillus bronchitis. Pain can affect your ability to sleep, move, breathe comfortably, and enjoy life. Understanding where it comes from and what to do — with the support of your medical team — can help you live better.

🔍 1. What Types of Pain Can Aspergillosis Cause?

🫁 Lung and Chest Pain

  • Inflammation, coughing strain, airway narrowing, or fungal cavities pressing on nearby tissues.

  • Often sharp or tight and worsens when breathing deeply or coughing.

🦴 Bone, Joint or Muscle Pain

  • Corticosteroids can thin bones or cause hip damage (avascular necrosis).

  • Long-term inflammation can lead to fatigue-related muscle aches.

🌪️ Rib or Postural Pain

  • Repetitive coughing can strain rib muscles or inflame the cartilage between ribs (costochondritis).

⚡ Nerve-related (Neuropathic) Pain

  • Tingling, burning, or electric sensations linked to medication side effects, nutritional deficiencies, or spinal involvement in rare cases.

🧠 2. Why Chronic Pain Happens: It’s Not Just Damage

Pain doesn’t always mean damage. In long-term conditions like aspergillosis, the nervous system can become “sensitised” — reacting too strongly to normal signals.

Central Sensitisation

  • Even after infection or inflammation is under control, the body may still send “danger” signals.

  • This creates chronic pain, even if scans or bloods look stable.

  • Stress, poor sleep, and fear increase this sensitivity.

✅ 3. What Patients Can Do to Reduce Pain

Physical Approaches

  • Breathing exercises and stretches (ask your physio)

  • Warm compresses and good posture support

  • Keep gently active to reduce joint and muscle stiffness

Medication and Supplements

  • Paracetamol for mild pain

  • Neuropathic pain drugs (amitriptyline, pregabalin)

  • Bone protection (vitamin D, bisphosphonates) if on steroids

  • Ask about alternatives if antifungals are causing nerve or joint pain

Emotional Support

  • Mindfulness or CBT for pain

  • Peer groups or patient support networks

🧑‍⚕️ 4. The Role of Your Healthcare Team in Managing Pain

Your doctors, nurses, physiotherapists and pharmacists all have a critical role in identifying and managing pain effectively:

👩‍⚕️ What They Should Be Doing:

1. Ask About Pain Proactively

  • Regularly check whether you're in pain — especially chest, rib, or hip pain

  • Ask about impact on sleep, mobility, mood, and appetite

2. Investigate the Cause of Pain

  • Order tests if pain is new, worsening, or unusual (e.g., MRI if hip pain on steroids)

  • Review antifungal and steroid side effects

  • Check for infections or changes in cavities that may cause bleeding or pleurisy

3. Prescribe Thoughtfully

  • Choose painkillers based on type of pain (nerve vs. inflammatory)

  • Avoid meds that interact with antifungals (e.g., NSAIDs with kidney issues)

  • Monitor for side effects of pain medicines, especially in long-term use

4. Refer as Needed

  • To pain clinic if your pain is long-term and not responding to treatment

  • To physio or occupational therapy for posture, rib support, or breathing retraining

  • To mental health support if pain is affecting your mood or coping

5. Educate and Empower

  • Provide information about central sensitisation and how pain works

  • Help you understand that managing pain does not mean ignoring disease activity — both are important

🛑 5. When to Seek Help Urgently

Call or see your doctor if:

  • Pain is new, sharp, or sudden

  • You’re coughing blood or have chest pain with breathing

  • Hip pain starts while on steroids (possible bone damage)

  • Pain is stopping you from sleeping, eating, or functioning

🧠 6. Take-Home Messages

  • Pain in aspergillosis is common, real, and manageable

  • It can come from disease, medications, or nervous system sensitisation

  • Patients and professionals must work together to address it

  • You do not have to suffer in silence — tell your team, track your pain, and ask for support

by GAtherton

Frequently Prescribed Antibiotics? Protect your Gut

If you're frequently prescribed antibiotics — as many bronchiectasis and ABPA patients are — protecting your gut health becomes very important. Long-term or repeated antibiotic use can disturb the gut microbiome, leading to problems such as diarrhoea, bloating, nutrient malabsorption, and even Clostridium difficile infection in severe cases.

Here’s what you can consider:

✅ 1. Consider Probiotics (with medical guidance)
Evidence is building that certain probiotics may help prevent antibiotic-associated gut symptoms, especially diarrhoea. Ask your team if it’s appropriate for you, particularly if you’ve had gut issues in the past.

⭐ Options often considered:

  • Lactobacillus rhamnosus GG
  • Saccharomyces boulardii (shown to reduce C. diff risk)
  • Lactobacillus casei, bifidobacteria combinations

💬 Take the probiotic a few hours after your antibiotic dose (not at the same time), and continue for at least a week after the course ends.

✅ 2. Eat to Feed the Good Bacteria
🥦 Focus on:

  • Prebiotic-rich foods (feed beneficial bacteria): oats, garlic, leeks, onions, bananas, apples, asparagus.
  • Fermented foods (contain live bacteria): live yoghurt, kefir, sauerkraut, kimchi, miso.

(Note: If immunocompromised or on antifungals, fermented foods should be used cautiously — check first.)

✅ 3. Stay Hydrated and Nourished

  • Diarrhoea or poor absorption can deplete fluids, electrolytes, and vitamins.
  • Consider a rehydration drink (like Dioralyte or homemade: 1 L water + 6 tsp sugar + ½ tsp salt).
  • Boost your intake of soluble fibre (e.g. oats, root veg) which is gentler on the gut during antibiotic courses.

✅ 4. Watch for Signs of C. difficile
If you have:

  • Watery diarrhoea (especially if frequent or smelly)
  • Abdominal pain
  • Fever

... call your GP or hospital team immediately — especially if you’re on long-term antibiotics like azithromycin or amoxicillin.

✅ 5. Consider Microbiome Restoration (in special cases)
If you’ve had multiple C. diff infections or your gut health is severely affected, faecal microbiota transplant (FMT) may be an option (NHS clinics offer this in select cases).

🚫 Avoid:

  • Overuse of antidiarrhoeals (like loperamide) without checking the cause.
  • High-sugar, highly processed foods — they feed the wrong bacteria.
  • Taking random probiotic supplements — many are poorly regulated and not all are helpful.

by GAtherton

Understanding Aspergillosis: A Guide for Expert Patients and Clinical Professionals

Aspergillosis is an umbrella term for a group of diseases caused by infection or hypersensitivity to fungi in the Aspergillus genus, most commonly Aspergillus fumigatus. The spectrum of disease ranges from benign colonisation to aggressive, life-threatening invasive infection, depending on the host’s immune status and pre-existing lung condition.

🔍 Main Forms of Aspergillosis

Type Description Typical Host
Allergic Bronchopulmonary Aspergillosis (ABPA) A hypersensitivity reaction to A. fumigatus in the airways, with airway inflammation and mucus plugging Asthma or cystic fibrosis patients
Chronic Pulmonary Aspergillosis (CPA) Long-term infection of damaged lung tissue; may form cavities, fibrosis, or fungal balls (aspergilloma) Patients with COPD, TB history, sarcoidosis, or bronchiectasis
Aspergilloma A fungal ball within a lung cavity, often seen in CPA Pre-existing lung cavity from TB or sarcoidosis
Invasive Aspergillosis (IA) Rapid tissue-invasive fungal infection, often bloodstream dissemination Immunocompromised hosts (neutropenia, transplant, high-dose steroids, haematological malignancy)
Sinopulmonary and Disseminated Aspergillosis Involvement of sinuses, CNS, bone, or multiple organs Usually in immunocompromised or advanced disease
Allergic Aspergillus Sinusitis (AAS) Similar to ABPA but in the sinuses Atopic individuals, often with nasal polyposis

👥 Who Is Vulnerable?

Risk varies by form:

1. ABPA

  • Adults or children with moderate-to-severe asthma

  • Patients with cystic fibrosis

2. CPA / Aspergilloma

  • Structural lung disease: TB scarring, COPD, sarcoidosis, bronchiectasis

  • Immune dysregulation: diabetes, corticosteroid use

3. Invasive Aspergillosis

  • Neutropenic patients (especially haematological malignancies)

  • Solid organ or stem cell transplant recipients

  • Chronic granulomatous disease

  • ICU patients (especially with influenza or COVID-19)

⚠️ Main Symptoms and Diagnostic Red Flags

Symptom Suggestive Of
Persistent cough, often productive ABPA or CPA
Wheeze, breathlessness, chest tightness ABPA
Haemoptysis (mild to severe) Aspergilloma, CPA, sometimes ABPA
Weight loss, fatigue, night sweats CPA or IA
Facial pain, nasal discharge Aspergillus sinusitis
Fever, hypoxia, sepsis signs Invasive aspergillosis

🧪 Diagnosis

📌 ABPA

  • Elevated total IgE (>1000 IU/mL)

  • Raised Aspergillus-specific IgE/IgG

  • Eosinophilia

  • Chest CT: central bronchiectasis, mucus impaction ("finger-in-glove")

  • Positive sputum culture or PCR for A. fumigatus

📌 CPA

  • Symptoms >3 months

  • Chest imaging: cavitary lesions, fungal ball, pleural thickening

  • Positive Aspergillus IgG

  • Repeated positive cultures/PCR from sputum or BAL

  • Exclusion of TB and other mimics

📌 Invasive Aspergillosis

  • Imaging: halo sign, air crescent sign on CT

  • Serum galactomannan, (1→3)-β-D-glucan, PCR

  • BAL galactomannan and culture

  • Tissue biopsy (definitive)

💊 Treatment Approaches

🟦 ABPA

  • Oral corticosteroids (mainstay)

  • Itraconazole or posaconazole to reduce fungal burden

  • Biologics (e.g. omalizumab, mepolizumab, benralizumab) in steroid-dependent or resistant cases

🟧 CPA

  • Long-term triazole antifungals (e.g. itraconazole, voriconazole, posaconazole)

  • Monitoring of serum drug levels, liver function

  • Surgical resection in selected cases (aspergilloma)

  • Inhaled amphotericin B in refractory cases

🟥 Invasive Aspergillosis

  • Voriconazole (first-line)

  • Liposomal amphotericin B (alternative)

  • Duration: typically 6–12 weeks

  • Manage immunosuppression, treat underlying disease

🧭 Monitoring and Follow-up

  • Serial imaging (CT or X-ray)

  • Aspergillus IgG/IgE titers

  • Liver function and antifungal serum levels

  • Patient-reported symptom scores and quality of life

📚 Further Information and Resources

  • National Aspergillosis Centre (NAC): aspergillosis.org,

  • UK Clinical Guidelines: BTS CPA Guidelines (2016), ERS ABPA position paper (2020)

  • Support Groups: NAC Patient Support Facebook Group, Aspergillosis Trust

  • Referral Pathway: Respiratory teams can refer to NAC via NHS e-Referral system or Advice & Guidance. NAC is a tertiary NHS service so referrals cannot be made by a GP.

by GAtherton

COVID-19 Associated Pulmonary Aspergillosis (CAPA) for Expert Patients and non-Specialist Clinicians

Expert Information for Patients, GPs, and Specialist Nurses

🔎 What Is CAPA?

CAPA is a form of invasive pulmonary aspergillosis (IPA) that develops in patients with severe COVID-19, particularly those in intensive care units (ICU) with acute respiratory distress syndrome (ARDS). It is an opportunistic fungal infection caused by Aspergillus fumigatus, occurring without traditional risk factors such as neutropenia.

CAPA is part of the broader group of IAPA (Influenza-Associated Pulmonary Aspergillosis) and VAPA (Viral-Associated Pulmonary Aspergillosis).

🧬 Pathophysiology

  • Severe viral pneumonia (COVID-19) damages the airway epithelium.

  • Inhaled Aspergillus spores invade damaged lung tissue.

  • Corticosteroids (e.g. dexamethasone), immunomodulators (e.g. tocilizumab), and prolonged ventilation increase susceptibility.

👥 Who Is at Risk?

Primarily affects patients with:

  • Severe COVID-19 pneumonia, especially those with:

    • ICU admission

    • Mechanical ventilation

    • ARDS

  • Corticosteroid therapy or IL-6 inhibitors (e.g. tocilizumab)

  • Underlying lung disease (COPD, asthma)

  • Diabetes mellitus

📍 CAPA may occur even in immunocompetent individuals due to local lung immune disruption.

⚠️ Clinical Features

Often non-specific and difficult to distinguish from worsening COVID-19:

  • Persistent or worsening respiratory failure

  • New pulmonary infiltrates on imaging

  • Fever despite antibacterial therapy

  • Haemoptysis or pleuritic chest pain (less common)

  • Increased oxygen or ventilatory support requirement

🧪 Diagnosis

CAPA is challenging to diagnose and relies on clinical suspicion, radiology, and mycological evidence.

Diagnostic Tools:

  • CT Chest:

    • Nodules, cavitations, halo sign (often non-specific in COVID)

  • Bronchoscopy with BAL:

    • Galactomannan (BAL GM ≥1.0 = probable CAPA)

    • Culture and PCR for Aspergillus

  • Serum Galactomannan or β-D-glucan:

    • May be positive but less sensitive than BAL

  • Histopathology (rarely obtained due to ICU setting)

Diagnostic Categories (ECMM/ISHAM 2020):

  • Proven: histology showing fungal invasion

  • Probable: radiology + mycology from BAL

  • Possible: suggestive clinical picture + limited microbiology

💊 Treatment

First-Line:

  • Voriconazole (IV or oral)

  • Isavuconazole (alternative with fewer side effects)

  • Consider liposomal amphotericin B if azole resistance or intolerance

Additional Considerations:

  • Therapeutic drug monitoring (TDM) required for voriconazole

  • Duration: typically 6–12 weeks depending on response and immune status

  • Minimise immunosuppression where possible

Empirical antifungal therapy may be started in ICU when suspicion is high, even before full confirmation.

🧾 Monitoring

  • Respiratory function

  • Repeat imaging to assess progression or resolution

  • Serum galactomannan

  • Liver function, renal function, and drug levels

  • Screen for drug interactions (especially with azoles)

📚 More Information

  • CAPA is a recently recognised entity, requiring close coordination between ICU, respiratory, and infectious disease teams.

  • Early antifungal treatment improves outcomes, but diagnosis is often delayed due to overlapping features with COVID-19 pneumonia.

  • Resources: ECMM/ISHAM CAPA definitions, aspergillosis.org

by GAtherton

Allergic Bronchopulmonary Aspergillosis (ABPA) for Expert Patients and non-Specialist Clinicians

Expert Information for Patients, GPs, and Specialist Nurses

🔎 What Is ABPA?

ABPA is a complex hypersensitivity reaction to Aspergillus fumigatus colonising the airways. It is not a fungal infection in the classic sense, but rather an exaggerated immune response — particularly involving IgE and eosinophils — seen in people with asthma or cystic fibrosis (CF).

It leads to recurrent inflammation, mucus plugging, and bronchial damage (including central bronchiectasis) if untreated.

🧬 Disease Mechanism

  • Type I and III hypersensitivity to A. fumigatus

  • Chronic airway inflammation causes mucus impaction and permanent lung damage

  • Associated with elevated total and specific IgE, eosinophilia, and recurrent flares

👥 Who Is at Risk?

  • Moderate to severe asthma

  • Cystic fibrosis

  • Rarely, patients with bronchiectasis or other chronic airway disease

ABPA is often underdiagnosed, especially in adults with difficult-to-control asthma.

⚠️ Common Symptoms

  • Worsening asthma control

  • Wheeze and chest tightness

  • Cough with thick mucus plugs

  • Shortness of breath

  • Intermittent low-grade fever

  • Haemoptysis (less common, usually mild)

  • Fatigue and poor response to inhaled steroids alone

🧪 Diagnosis

Diagnosis is based on a combination of clinical, radiological, and immunological features.

Core Investigations:

  1. Total IgE ≥1000 IU/mL (or >500 in treated patients)

  2. Aspergillus-specific IgE positive

  3. Aspergillus-specific IgG (or precipitating antibodies)

  4. Blood eosinophilia (>0.5 x10⁹/L typically)

  5. Chest CT: central bronchiectasis, mucus plugging (“finger-in-glove”), fleeting infiltrates

  6. Sputum culture or PCR positive for A. fumigatus

Diagnostic Criteria:

Use updated ISHAM criteria (2024 version preferred) combining major and minor features.

💊 Treatment

First-Line:

  • Oral corticosteroids (e.g. prednisolone) – cornerstone of flare management

    • Typically tapered over 3–6 months

Adjunct:

  • Itraconazole or posaconazole – reduces antigen burden and steroid need

    • 3–6 months or longer; monitor liver function and drug levels

Steroid-Sparing Options:

  • Biologics (increasingly used, especially in steroid-dependent or relapsing patients):

    • Omalizumab (anti-IgE)

    • Mepolizumab, Benralizumab (anti-IL-5)

    • Dupilumab, Tezepelumab (emerging options)

🧾 Monitoring

  • Total IgE every 1–3 months (a 25–50% rise may indicate relapse)

  • Pulmonary function tests (FEV1, peak flow)

  • Repeat CT if clinical deterioration or poor steroid response

  • Sputum cultures in persistent symptoms (to exclude Aspergillus bronchitis)

⚠️ Complications

  • Progression to bronchiectasis

  • CPA (if antifungals are stopped prematurely in chronic cases)

  • Recurrent flares leading to irreversible damage

  • Steroid side effects (weight gain, osteoporosis, adrenal suppression)

📚 More Information

  • Specialist referral: patients should be considered for referral to the National Aspergillosis Centre (NAC) or local respiratory immunology team for persistent/recurrent ABPA.

  • Patient support: aspergillosis.org, CF Trust, Asthma + Lung UK

  • Key guidelines: Guidance

by GAtherton

Aspergillus Tracheobronchitis (ATB) for Expert patients and non-Specialist Clinicians

Expert Information for Patients, GPs, and Specialist Nurses

🔎 What Is Aspergillus Tracheobronchitis?

Aspergillus tracheobronchitis (ATB) is a rare but serious form of airway-invasive aspergillosis that primarily affects the trachea and large bronchi, rather than the lung parenchyma. It occurs predominantly in immunocompromised patients and may present with obstructive airway symptoms or respiratory failure.

ATB can exist on a spectrum from superficial colonisation to ulcerative or pseudomembranous invasion of the bronchial wall.

🧬 Pathophysiology

  • Inhaled Aspergillus spores adhere to and invade damaged airway mucosa.

  • Occurs more commonly when local airway immunity is impaired (e.g. in transplant recipients or critical illness).

  • May co-exist with invasive pulmonary aspergillosis (IPA) or appear in isolation.

👥 Who Is at Risk?

High-risk groups include:

  • Lung transplant recipients

  • Hematopoietic stem cell transplant patients

  • Severe COPD or structural airway disease

  • Patients with prolonged corticosteroid use

  • Critically ill or mechanically ventilated patients

  • COVID-19 or influenza patients (sometimes overlapping with CAPA/IAPA)

⚠️ Clinical Presentation

Symptoms depend on the degree of airway obstruction and depth of invasion:

  • Cough (dry or productive)

  • Worsening breathlessness

  • Stridor or wheeze

  • Hoarseness or vocal changes

  • Fever unresponsive to antibiotics

  • Haemoptysis (may be life-threatening)

  • Airway obstruction or collapse in advanced cases

ATB may be mistaken for tracheobronchial malignancy, infection, or stenosis.

🧪 Diagnosis

Bronchoscopy is essential for diagnosis:

  • Direct visualisation of:

    • Ulceration

    • Pseudomembranes

    • Plaques

    • Necrotic debris

  • Biopsies may reveal fungal hyphae invading mucosa.

Microbiological Investigations:

  • Culture and PCR for Aspergillus from BAL or brushings

  • BAL galactomannan

  • Serum galactomannan or β-D-glucan may be supportive

  • CT chest may be normal or show airway thickening, bronchial wall invasion, or tree-in-bud opacities

💊 Treatment

Systemic Antifungals:

  • Voriconazole is first-line

  • Isavuconazole or liposomal amphotericin B if azole intolerant or resistant

Airway Management:

  • Debridement or bronchoscopic removal of pseudomembranes in severe obstruction

  • Airway stenting in refractory strictures

  • Nebulised antifungals (e.g. amphotericin B) may be used as adjunct in selected cases

Prompt initiation of antifungal therapy is vital. Delays can lead to respiratory failure or death.

🧾 Monitoring

  • Clinical response: breathlessness, cough, fever

  • Repeat bronchoscopy in some cases

  • CT imaging of airways

  • Antifungal drug levels

  • Liver and renal function

📚 More Information

  • ATB is under-recognised, especially in non-neutropenic or critically ill patients.

  • Should be considered in transplant recipients or ICU patients with persistent respiratory symptoms and negative bacterial cultures.

  • Referral to respiratory, infectious diseases, and ICU teams is essential.

  • Resources: aspergillosis.org ; BTS Statement on  aspergillosis

by GAtherton

Aspergillus Bronchitis for Expert Patients and non-Specialist Clinicians

Expert Information for Patients, GPs, and Specialist Nurses

🔎 What Is Aspergillus Bronchitis?

Aspergillus bronchitis is a chronic fungal infection of the airways by Aspergillus fumigatus (or rarely other Aspergillus species), seen in individuals with structural lung disease or impaired mucociliary clearance. Unlike ABPA, it is not allergic in origin and does not involve systemic invasion, but is characterised by persistent fungal colonisation with active infection.

🧬 Pathophysiology

  • Chronic colonisation of the conducting airways by Aspergillus

  • Local immune dysfunction (but not systemic immunosuppression)

  • Low-grade inflammation and increased mucus production

  • Often coexists with bronchiectasis, COPD, or CF

👥 Who Is at Risk?

Most commonly seen in patients with:

  • Bronchiectasis (non-ABPA)

  • Cystic fibrosis

  • COPD or asthma with sputum production

  • Post-viral or structural airway damage

  • Chronic antibiotic or corticosteroid use

Not typically seen in severely immunocompromised hosts (in whom invasive aspergillosis is more likely).

⚠️ Common Symptoms

  • Persistent productive cough

  • Thick sputum often yellow or green

  • Worsening breathlessness or wheeze

  • Chronic sputum positivity for Aspergillus

  • Mild fever or malaise (but often afebrile)

  • Poor response to antibiotics alone

Symptoms may resemble chronic bacterial bronchitis or overlap with infective exacerbations of bronchiectasis.

🧪 Diagnosis

Diagnosis requires a combination of clinical and microbiological evidence, with exclusion of ABPA and CPA.

Diagnostic Features:

  1. Chronic productive cough (>4 weeks)

  2. Repeated isolation of Aspergillus from sputum or BAL

  3. Elevated Aspergillus IgG (typically present)

  4. Normal or mildly elevated total IgE (typically <1000 IU/mL)

  5. Absence of cavitary lesions or ABPA features on CT

  6. Response to antifungal treatment supports diagnosis

🛑 Exclude:

  • ABPA (IgE >1000, eosinophilia, central bronchiectasis)

  • CPA (cavities, weight loss, radiological progression)

💊 Treatment

First-Line:

  • Oral antifungals (usually for 3–6 months)

    • Itraconazole (first choice)

    • Voriconazole or posaconazole (if resistant/intolerant)

  • Monitor drug levels and LFTs

Adjuncts:

  • Physiotherapy and airway clearance techniques

  • Nebulised saline or mucolytics

  • Treat co-infections (e.g. Pseudomonas) where relevant

In patients with CF, consider co-management with a specialist CF team.

🧾 Monitoring

  • Sputum cultures to monitor persistence or clearance

  • Aspergillus IgG levels

  • Symptoms (sputum, breathlessness)

  • Liver function and drug monitoring

  • Periodic CT imaging if symptoms worsen or haemoptysis occurs

📚 More Information

by GAtherton

Aspergillus Sinusitis for Expert Patients and non-Specialist Clinicians

Expert Information for Patients, GPs, and Specialist Nurses

🔎 What Is Aspergillus Sinusitis?

Aspergillus sinusitis refers to fungal involvement of the paranasal sinuses by Aspergillus species, especially A. fumigatus. It spans a spectrum from benign colonisation to destructive invasive disease, depending on the host’s immune status.

There are four main clinical forms, with distinct presentations and treatment approaches.

🧬 Main Forms

Type Description Typical Host
Allergic Fungal Rhinosinusitis (AFRS) A hypersensitivity reaction with nasal polyps and allergic mucin Atopic patients (often young adults)
Fungal Ball (Mycetoma) A dense fungal plug within a sinus cavity, non-invasive Immunocompetent individuals
Chronic Invasive Fungal Sinusitis Slowly progressive mucosal and bony invasion Diabetics, immunosuppressed
Acute Invasive Fungal Sinusitis Rapidly destructive, vascular invasion, necrosis Severely immunocompromised (e.g. neutropenic, transplant recipients)

👥 Who Is at Risk?

Depends on form:

🟩 AFRS:

  • Asthma, eczema, allergic rhinitis

  • Nasal polyps

  • Fungal IgE sensitisation (esp. Aspergillus)

🟨 Fungal Ball:

  • Older adults

  • Dental work (esp. upper molars with root involvement)

  • Chronic sinus blockage or prior surgery

🟧 Chronic Invasive:

  • Long-term corticosteroid or immunosuppressive use

  • Poorly controlled diabetes

🟥 Acute Invasive:

  • Haematological malignancies

  • Bone marrow/stem cell transplant

  • Neutropenia or severe COVID-19

⚠️ Clinical Features

Symptom Common To
Nasal congestion, discharge All forms
Facial pain or pressure All forms
Nasal polyps AFRS
Foul smell or thick mucus Fungal ball
Eye pain, proptosis, visual changes Invasive forms
Fever, systemic illness Invasive forms
Black eschar or necrosis Acute invasive sinusitis (medical emergency)

🧪 Diagnosis

Initial Evaluation:

  • Nasal endoscopy: mucosal thickening, polyps, or black necrosis

  • CT scan: sinus opacification, bone erosion, hyperdense lesions

  • MRI: assesses orbital or intracranial extension in invasive cases

Microbiology & Histopathology:

  • Direct microscopy or fungal stain (e.g. GMS)

  • Culture for Aspergillus spp.

  • Aspergillus-specific IgE/IgG in AFRS

  • Tissue biopsy is essential in invasive disease

💊 Treatment

🟩 AFRS:

  • Functional endoscopic sinus surgery (FESS) to clear sinuses

  • Oral and topical corticosteroids

  • Antifungals (controversial; may reduce recurrence)

  • Allergen immunotherapy in selected cases

🟨 Fungal Ball:

  • Surgical removal only (FESS)

  • No systemic antifungal needed unless complications arise

🟧 Chronic Invasive:

  • Surgical debridement

  • Long-term oral antifungals (e.g. voriconazole, posaconazole)

  • Monitor drug levels and imaging

🟥 Acute Invasive:

  • Urgent surgical debridement

  • High-dose IV antifungals (voriconazole or liposomal amphotericin B)

  • Reversal of immunosuppression

  • High mortality if delayed — requires ICU and ID team coordination

🧾 Monitoring

  • Repeat imaging for resolution (especially invasive forms)

  • Symptom scores for AFRS and post-FESS recovery

  • Antifungal levels and LFTs if systemic therapy used

  • Endoscopic surveillance in high-risk or relapsing patients

📚 More Information

by GAtherton

🌐 Trusted Online Resources for Palliative and Supportive Care

1. Marie Curie UK

🔗 https://www.mariecurie.org.uk
One of the UK’s leading providers of end-of-life support.

  • Clear guides on what palliative care is

  • Advice on symptom management, emotional support, and practical issues

  • Online chat and helpline: 0800 090 2309

  • Information for families and carers

2. Hospice UK

🔗 https://www.hospiceuk.org
National charity supporting over 200 hospices in the UK.

  • Search tool to find local hospice services

  • Guidance on advance care planning, DNACPR, and choosing care settings

  • Support for people receiving palliative care at home

3. NHS: Palliative and End of Life Care

🔗 https://www.nhs.uk/conditions/end-of-life-care/
Official NHS overview of palliative care.

  • Describes when and how palliative care is offered

  • Explains where care can happen (home, hospital, hospice)

  • Advice on legal planning, such as Advance Decisions and Lasting Power of Attorney

4. Dying Matters / Good Life, Good Death, Good Grief (Scotland)

🔗 https://www.goodlifedeathgrief.org.uk
Scottish-based initiative that helps people plan ahead.

  • Leaflets on how to talk about death and dying

  • "Planning Ahead" toolkit for people with long-term illness

  • Supports both patients and professionals

5. Compassion in Dying

🔗 https://www.compassionindying.org.uk
Specialist in advance care planning and patient rights.

  • Downloadable Advance Statement and Advance Decision forms

  • Free support to write a Living Will

  • Helpline: 0800 999 2434

6. Palliative Care Adult Network Guidelines (PCANG)

🔗 https://book.pallcare.info/
Clinical guidelines, but useful for patients seeking clarity on symptom control (e.g. breathlessness, cough, fatigue).

7. Silver Chain (International)

🔗 https://www.silverchain.org.au/
Australian site with good explainer videos and practical patient stories — relevant to any patient needing home-based palliative care or telehealth.

by GAtherton

Chronic Pulmonary Aspergillosis (CPA) for Expert Patients and Non-Specialist Clinicians

Expert Information for Patients, GPs, and Specialist Nurses

🔎 What Is CPA?

Chronic Pulmonary Aspergillosis (CPA) is a long-term fungal lung infection caused by Aspergillus, typically A. fumigatus. It occurs in individuals with underlying lung damage and can progress slowly over months to years. It includes several subtypes ranging from cavitary lesions to fibrosing disease and fungal balls (aspergillomas).

🧬 Subtypes of CPA

Subtype Description
Simple aspergilloma Fungal ball within a pre-existing lung cavity
Chronic cavitary pulmonary aspergillosis (CCPA) Multiple cavities ± fungal balls; progressive
Chronic fibrosing pulmonary aspergillosis Advanced form with fibrosis and volume loss
Subacute invasive aspergillosis (SAIA) Intermediate between CPA and invasive disease; more rapid progression over weeks to months
Aspergillus nodules Discrete nodules without cavitation; may mimic malignancy

👥 Who Is at Risk?

CPA typically affects people with pre-existing lung disease or immune dysfunction, including:

  • Tuberculosis (old or active)

  • COPD and emphysema

  • Bronchiectasis

  • Sarcoidosis

  • Prior pneumothorax

  • Lung cancer or surgery

  • Diabetes mellitus

  • Low-dose or chronic steroid use

⚠️ Common Symptoms

CPA symptoms often evolve insidiously over >3 months:

  • Chronic productive cough

  • Haemoptysis (may be mild or massive)

  • Fatigue and weight loss

  • Breathlessness

  • Chest discomfort

  • Fever (occasional)

🧪 Diagnosis

Diagnosis of CPA requires the combination of:

  1. Symptoms ≥3 months

  2. Imaging:

    • CT chest: cavitary lesions, pleural thickening, aspergilloma, fibrotic changes

  3. Microbiology:

    • Positive sputum culture, PCR, or histopathology for A. fumigatus

  4. Serology:

    • Elevated Aspergillus IgG antibodies (essential for diagnosis)

  5. Exclusion of other diseases:

    • Especially active TB, malignancy, and bacterial infections

💊 Treatment

First-Line:

  • Oral triazole antifungals (minimum 6 months, often longer)

    • Itraconazole

    • Voriconazole

    • Posaconazole

  • Therapeutic drug monitoring is crucial

Additional:

  • Inhaled antifungals (e.g. amphotericin B) in selected cases

  • Surgery for localised disease or life-threatening haemoptysis (if fit)

  • Bronchial artery embolisation for bleeding control

  • Physiotherapy and nutritional support

🧾 Monitoring

  • CT scan every 3–6 months during treatment

  • Aspergillus IgG titres to monitor disease activity

  • Liver function and antifungal levels (monthly at minimum)

  • Symptom tracking (cough, energy, weight, breathlessness)

📚 More Information

by GAtherton